Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy

被引：4

作者：

Li, Zihai ^{[1
,2
]}

Azar, Joseph H. ^{[1
,2
]}

Rubinstein, Mark P. ^{[1
,2
]}

机构：

[1] Ohio State Univ, Div Med Oncol, Dept Internal Med, Columbus, OH USA

[2] Ohio State Univ, James Comprehens Canc Ctr, Plotonia Inst Immunooncol, 460 W 12th Ave,BRT 510,Biomed Res Tower, Columbus, OH 43210 USA

来源：

CANCER DISCOVERY | 2022年 / 12卷 / 05期

关键词：

D O I：

10.1158/2159-8290.CD-22-0219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dose-limiting toxicities are thought to temper the efficacy of single-agent 4-1BB agonists. To overcome this hurdle, in this issue of Cancer Discovery, Muik and colleagues report preclinical and clinical studies describing a first-in-class bispecific fusion protein targeting 4-1BB and PD-L1.

引用

页码：1184 / 1186

页数：3

共 50 条

[1] PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy
Shu, Fei
Punekar, Salman R.
Velcheti, Vamsidhar
Sanmamed, Miguel F.
Wang, Jun
CLINICAL CANCER RESEARCH, 2022, 28 (15) : 3182 - 3184
[2] Role of 4-1BB:4-1BB ligand in cancer immunotherapy
Adam T C Cheuk
Ghulam J Mufti
Barbara-ann Guinn
Cancer Gene Therapy, 2004, 11 : 215 - 226
[3] Role of 4-1BB:4-1BB ligand in cancer immunotherapy
Cheuk, ATC
Mufti, GJ
Guinn, BA
CANCER GENE THERAPY, 2004, 11 (03) : 215 - 226
[4] Immunotherapy of Cancer with 4-1BB
Vinay, Dass S.
Kwon, Byoung S.
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (05) : 1062 - 1070
[5] Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity
Rubio-Perez, Laura
Frago, Susana
Compte, Marta
Navarro, Rocio
Harwood, Seandean L.
Lazaro-Gorines, Rodrigo
Gomez-Rosel, Marina
Hangiu, Oana
Silva-Pilipich, Noelia
Vanrell, Lucia
Smerdou, Cristian
Alvarez-Vallina, Luis
ANTIBODIES, 2024, 13 (02)
[6] 4-1BB: A promising target for cancer immunotherapy
Kim, Alyssa Min Jung
Nemeth, Macy Rose
Lim, Seung-Oe
FRONTIERS IN ONCOLOGY, 2022, 12
[7] Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
Warmuth, Stefan
Gunde, Tea
Snell, Daniel
Brock, Matthias
Weinert, Christopher
Simonin, Alexandre
Hess, Christian
Tietz, Julia
Johansson, Maria
Spiga, Fabio Mario
Heiz, Robin
Fluckiger, Naomi
Wagen, Sandro
Zeberer, Julia
Diem, Dania
Mahler, Dana
Wickihalder, Belinda
Muntwiler, Simone
Chatterjee, Bithi
Kuttner, Benjamin
Bommer, Bettina
Yaman, Yasemin
Lichtlen, Peter
Urech, David
ONCOIMMUNOLOGY, 2021, 10 (01):
[8] KEY PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS THAT CORRELATE WITH THE ANTI-TUMOR ACTIVITY OF A BISPECIFIC PD-L1 CONDITIONAL 4-1BB AGONIST
Kinkead, Heather
Macedo, Chelsie
Sanabria, Angelica
Cyprus, Garrett
Pandit, Rajay
Kalabus, James
Becklund, Bryan
Sulzmaier, Florian
Timmer, John
Deveraux, Quinn
Eckelman, Brendan
Heidt, Analeah
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A12 - A12
[9] 4-1BB agonism: adding the accelerator to cancer immunotherapy
Chester, Cariad
Ambulkar, Siddhant
Kohrt, Holbrook E.
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (10) : 1243 - 1248
[10] 4-1BB agonism: adding the accelerator to cancer immunotherapy
Cariad Chester
Siddhant Ambulkar
Holbrook E. Kohrt
Cancer Immunology, Immunotherapy, 2016, 65 : 1243 - 1248

← 1 2 3 4 5 →